As an approach to selectively target CD47 on cancer cells, we have developed a fully human IgG1 bispecific antibody (bsAb) platform, which takes advantage of the fully competent Fc effector functions of human IgG1 and avoids on-target/off-tumor toxicity of CD47 [23]. Here, CD47 is linked to cancer.